Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

On July 14, 2020 Sanofi and The University of Texas MD Anderson Cancer Center reported a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune-therapies, for patients with cancer (Press release, Sanofi, JUL 14, 2020, View Source [SID1234561852]). The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our goal is to improve the outcome for patients with a range of difficult-to-treat cancers, which is best achieved through a deep understanding of how investigational new drugs work," said Peter Adamson, M.D., Global Development Head, Oncology and Pediatric Innovation at Sanofi. "This alliance leverages MD Anderson’s agile approach to early phase clinical trials, their laboratory capabilities and broad scientific expertise. This will get us to go/no-go decisions much faster and help us identify potential new combinations and indications more accurately. That will save precious time and help us expand the spectrum of patients who could potentially benefit from our therapies."

MD Anderson manages one of the country’s largest oncology clinical trial programs, with well-established platforms for tissue collection, molecular and immune profiling, and data analysis. This infrastructure enables the comprehensive study of tumor samples taken before, during and after treatment to uncover valuable insights that help streamline patient selection and hasten the identification of new therapy combinations and indications.

"Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients," said Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics. "We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies."

The new alliance also will support investigations into additional indications and combinations for studies already in the clinic. Sanofi and MD Anderson scientists will collaborate on experimental design, applying a core set of biomarkers and assays. Joint projects also will apply novel investigational agents developed at Sanofi to existing tumor samples to obtain further data on their effects at different disease stages.

"MD Anderson’s expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues," said Dmitri Wiederschain, Ph.D., Global Head of Immuno-Oncology Research at Sanofi. "The knowledge we gain in this collaboration will also deepen our shared understanding of cancers’ potential vulnerabilities."

New findings, as well as large-scale molecular and phenotype datasets, will be applied to the design of new translational studies on selected Sanofi molecules, and guide the selection of indications. The collaboration is expected to launch its first projects in summer 2020.

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies

On July 14, 2020 Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) technology platform and JW Therapeutics, a biotechnology company focusing on the development, transformation and promotion of cell immunotherapy, have reported a collaboration to develop and commercialize ACE1702 and ACE1655, two of Acepodia’s cell therapy candidates for the treatment of solid tumors and hematologic malignancies, respectively, in Mainland China, Hong Kong, and Macau (Press release, Acepodia, JUL 14, 2020, View Source [SID1234616138]). Acepodia will receive upfront and milestone payments in addition to royalties on sales

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Acepodia’s allogeneic cell therapy platform is based on optimizing its proprietary, potent and off-the-shelf natural killer cell line (oNK cells) with tumor-targeting mechanisms through its antibody-cell conjugation (ACC) technology that links antibodies directly to the surface proteins of immune cells to enhance their tumor-killing ability.

"We are excited to partner with Acepodia to advance NK cell-based therapies through the clinic, with the goal of eventually introducing these innovative therapies to patients. Acepodia has applied a broad and integrative approach to providing more potential clinical treatment options for solid tumors and hematologic malignancies, with the ability to scale up production of these targeted cell-therapies, as needed," said James Li, M.D., chief executive officer of JW Therapeutics.

Sonny Hsiao, Ph.D., chief executive officer of Acepodia added, "This partnership perfectly captures the synergies between Acepodia and JW Therapeutics. By combining our research capabilities and novel cell therapy platform with JW Therapeutics’ translational cancer immunology research and development capacity, this collaboration is aptly suited to develop and commercialize our oNK cell therapies in these regional markets. We look forward to working with JW Therapeutics to advance these therapies through the clinic, maximizing their allogeneic and ‘off-the-shelf’ treatment potential."

ImmunSYS Announces it Hosted a Virtual Analyst Day Event on July 7, 2020

On July 14, 2020 ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, reported that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020 (Press release, ImmunSYS, JUL 14, 2020, View Source;utm_medium=rss&utm_campaign=immunsys-announces-it-hosted-a-virtual-analyst-day-event-on-july-7-2020 [SID1234561854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President of ImmunSYS provided a business overview and highlighted upcoming milestones. Two world-renowned, key opinion leaders, E. David Crawford, M.D. Professor of Urology at the University of San Diego, and Steven J. O’Day, M.D., Executive Director of the John Wayne Cancer Institute and Cancer Clinic provided updates on the current prostate cancer landscape and reviewed new data on the company’s platform technology, YourVaccx. Dr. O’Day provided an in-depth review of the company’s Proof of Concept (PoC) study data that was recently presented at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting II.

A replay of the event can be accessed on the ImmunSYS website in the ‘Publications’ section at www.immunsys.com/publications

Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock

On July 14, 2020 Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported the commencement of a proposed underwritten public offering of 8,000,000 shares of its common stock (6,000,000 of which are being offered for sale by Adaptive and 2,000,000 of which are being offered for sale by a selling shareholder) (Press release, Adaptive Biotechnologies, JUL 14, 2020, View Source [SID1234561952]). In addition, Adaptive expects to grant the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adaptive intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Adaptive, primarily to accelerate investments in Adaptive’s TCR-Antigen Map activities, scale commercial and marketing activities associated with immunoSEQ Dx clinical products and services, and support continued research and development for drug discovery initiatives. A portion of the net proceeds may also be used to scale Adaptive’s laboratory operations and capacity to support commercial growth plans and for working capital and other general corporate purposes. Adaptive will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling shareholder.

J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are acting as joint lead book-running managers for the offering.

The public offering is being made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Adaptive with the U.S. Securities and Exchange Commission (SEC) on July 14, 2020 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Upterra Secures Series A Investment and Company Introduction

On July 14, 2020 Uppthera reported the company co-founded by five former celltrion researchers. Raised 12.7 billion KRW in Series A funding just two years after establishment in 2018. Developing new drugs for small cell lung cancer, hyperlipidemia and multiple myeloma and establishing a novel E3L PROTAC platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Uppthera, JUL 14, 2020, View Source [SID1234664776])